Scholars Central

Conference abstractPublished 23 Sep 2013

Post-approval safe harbor…or not?

Authors: Brian R. Dorn

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Section 271(e)(1) of United States Code Title 35 provides a safe harbor when infringement is reasonably related to a FDA submission. This past session, the United States Supreme Court denied certiorari to two patent infringement cases claiming a safe harbor in regards to a drug post-FDA approval.Both accused infringers contend that if they infringed, the infringement was to provide FDA with post-approval data. The Court of Appeals for the Federal Circuit denied safe harbor in Classen but allowed safe harbor in Amphastar . The U.S. government asserts that the two Federal Circuit decisions can be reconciled. However, there are two distinct judicial views on the Federal Circuit. This session will address whether the two decisions are reconcilable or if there is a continued split in the law.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Bioanalysis & Biomedicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “Brian R. Dorn”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels